Evidence map›Paper›PMID 33106821›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Diagnostic utility of a Ferritin-to-Procalcitonin Ratio to differentiate patients with COVID-19 from those with Bacterial Pneumonia: A multicenter study.

Amal A Gharamti, Fei Mei, Katherine C Jankousky, Jin Huang, Peter Hyson, Daniel B Chastain, Jiawei Fan, Sharmon Osae, Wayne W Zhang, José G Montoya and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Amal A GharamtiDepartment of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Fei MeiDepartment of Vascular Surgery, Yichang Central People's Hospital, The first College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China.
Katherine C JankouskyDepartment of Medicine, School of Medicine, University of Colorado, Anschutz Medical Center Aurora, CO, USA.
Jin HuangSchool of Medicine, University of Colorado, Anschutz Medical Center Aurora, CO, USA.
Peter HysonDepartment of Medicine, School of Medicine, University of Colorado, Anschutz Medical Center Aurora, CO, USA.
Daniel B ChastainDepartment of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, GA, USA.
Jiawei FanDepartment of Vascular Surgery, Yichang Central People's Hospital, The first College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China.
Sharmon OsaeDepartment of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, GA, USA.
Wayne W ZhangDivision of Vascular and Endovascular Surgery, Department of Surgery, University of Washington and Puget Sound VA Health Care System, Seattle, WA, USA.
José G MontoyaCo-director, Dr. Jack S. Remington Laboratory for Specialty Diagnostics, Palo Alto, California.
Kristine M ErlandsonDivision of Infectious Diseases, University of Colorado, Anschutz Medical Center Aurora, CO, USA.
Sias J SchergerDivision of Infectious Diseases, University of Colorado, Anschutz Medical Center Aurora, CO, USA.
Carlos Franco-ParedesDivision of Infectious Diseases, University of Colorado, Anschutz Medical Center Aurora, CO, USA.
Andrés F Henao-MartínezDivision of Infectious Diseases, University of Colorado, Anschutz Medical Center Aurora, CO, USA.ORCID 0000-0001-7363-8652
Leland ShapiroDivision of Infectious Diseases, University of Colorado, Anschutz Medical Center Aurora, CO, USA.
University of Colorado Anschutz Medical Campus · USChina Three Gorges University · CNGeorgia College & State University · USAmerican University of Beirut · LBHospital Infantil de México Federico Gómez · MXUniversity of Washington · US

Funding

Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID SurvivorsR01AG054366 · NIA · UNIVERSITY OF COLORADO DENVER · PI ERLANDSON, KRISTINE MACE · 2016 to 2020
$3.4M
NIA NIH HHS R01 AG054366
6 · The paper itself

Abstract

importanceThere is a need to develop tools to differentiate COVID-19 from bacterial pneumonia at the time of clinical presentation before diagnostic testing is available.

objectiveTo determine if the Ferritin-to-Procalcitonin ratio (F/P) can be used to differentiate COVID-19 from bacterial pneumonia.

designThis case-control study compared patients with either COVID-19 or bacterial pneumonia, admitted between March 1 and May 31, 2020. Patients with COVID-19 and bacterial pneumonia co-infection were excluded.

settingA multicenter study conducted at three hospitals that included UCHealth and Phoebe Putney Memorial Hospital in the United States, and Yichang Central People's Hospital in China.

participantsA total of 242 cases with COVID-19 infection and 34 controls with bacterial pneumonia. MAIN OUTCOMES AND MEASURES: The F/P in patients with COVID-19 or with bacterial pneumonia were compared. Receiver operating characteristic analysis determined the sensitivity and specificity of various cut-off F/P values for the diagnosis of COVID-19 versus bacterial pneumonia.

resultsPatients with COVID-19 pneumonia had a lower mean age (57.11 vs 64.4 years, p=0.02) and a higher BMI (30.74 vs 27.15 kg/m CONCLUSIONS AND RELEVANCE: An F/P ≥ 877 increases the likelihood of COVID-19 pneumonia compared to bacterial pneumonia. Further research is needed to determine if obtaining ferritin and procalcitonin simultaneously at the time of clinical presentation has improved diagnostic value. Additional questions include whether an increased F/P and/or serial F/P associates with COVID-19 disease severity or outcomes.

Identifiers

PMID33106821
PMCPMC7587841
OpenAlexW3094340475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.